Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. APTX:CN
3. IQMX
4. EROC
5. SEER
6. FRBT
7. MSTR
8. SPY
9. ONDS
10. MSFT

Go back to Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

Moderna (MRNA) Extends Gain, Up 6.5%

November 14, 2022 12:06 PM EST

Moderna (NASDAQ: MRNA) Extends Gain, Up 6.5%

... More